Reversed liquid crystalline phases with non-paraffin hydrophobes
First Claim
1. A composition comprising:
- a reversed cubic phase or reversed hexagonal phase material, or a combination thereof, comprised of a polar solvent, a surfactant, and a non-paraffinic liquid with a high octanol-water partition coefficient which does not qualify as a surfactant; and
a compound that is difficultly soluble in water solubilized in said reversed cubic phase or reversed hexagonal phase material, or a combination thereof.
1 Assignment
0 Petitions
Accused Products
Abstract
Compounds which are otherwise difficult to solubilize, such as, for example, pharmaceutical actives difficult for the body to absorb, are solubilized into a composition using a solvent system that is a structured fluid. The structured fluid is a reversed cubic phase or reversed hexagonal phase material, or a combination thereof, which includes a polar solvent, a surfactant and a non-paraffinic liquid with a high octanol-water partition coefficient which does not qualify as a surfactant. The compositions thus formed are able to enhance absorption of drugs by the induction of local, transient nanopores in biomembrane absorption barriers and particularly those in which efflux mechanisms, such as those associated with P-glycoprotein and/or cytochrome 3A4, are active. The compositions and methods that are used for solubilizing pharmaceutical actives in structured fluids can simultaneously accomplish solubilization of difficultly soluble drugs and enhancement of absorption.
86 Citations
79 Claims
-
1. A composition comprising:
-
a reversed cubic phase or reversed hexagonal phase material, or a combination thereof, comprised of a polar solvent, a surfactant, and a non-paraffinic liquid with a high octanol-water partition coefficient which does not qualify as a surfactant; and
a compound that is difficultly soluble in water solubilized in said reversed cubic phase or reversed hexagonal phase material, or a combination thereof. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 39, 74)
-
-
20. A composition, comprising:
-
a polar solvent;
a surfactant; and
a non-paraffinic liquid with a polar group that is not operative as a surfactant head group and with a high octanol-water partition coefficient which does not qualify as a surfactant, wherein the composition is present as a reversed cubic or reversed hexagonal liquid crystalline phase, or a combination thereof. - View Dependent Claims (21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)
-
-
35. A composition, comprising:
-
a reversed cubic phase or reversed hexagonal phase material composed of pharmaceutically acceptable components, or a combination thereof, comprised of a polar solvent, a surfactant, and a non-paraffinic liquid having a polar group that is not operative as a surfactant head group, and with a high octanol-water partition coefficient which does not qualify as a surfactant; and
a compound that is difficultly soluble in water solubilized in said reversed cubic phase or reversed hexagonal phase material, or a combination thereof. - View Dependent Claims (36, 37, 38, 75)
-
-
40. A method for solubilizing a difficultly soluble compound comprising the step of incorporating said difficultly soluble compound into a matrix comprised of a reversed cubic or reversed hexagonal liquid crystalline phase material, or a combination thereof, wherein the reversed cubic or reversed hexagonal liquid crystalline phase material comprises a polar solvent, a surfactant, and a non-paraffinic liquid with a high octanol-water partition coefficient which does not qualify as a surfactant.
-
41. A method for administering a pharmaceutical active compound to a patient, comprising the steps of:
-
providing said patient with said pharmaceutical active compound associated with a reversed cubic phase or reversed hexagonal phase material, or a combination thereof, and inducing nanopores in biomembrane absorption barriers in cells or tissues or organs of said patient using said reversed cubic phase or reversed hexagonal phase material, or a combination thereof, wherein said nanopores permit said pharmaceutical active compound to pass therethrough. - View Dependent Claims (42, 43, 44, 45, 46, 47, 76)
-
-
48. A method for transporting a compound through a biomembrane absorption barrier, comprising the steps of:
-
inducing nanopores in said biomembrane absorption barrier using a reversed cubic phase or reversed hexagonal phase material, or a combination thereof, which is associated with said compound; and
passing said compound through said nanopores. - View Dependent Claims (49, 50, 51, 52, 53, 54, 77)
-
-
55. A method for administering a pharmaceutical active compound to a patient, comprising the steps of:
-
providing said patient with said pharmaceutical active compound;
providing said patient with a reversed cubic phase or reversed hexagonal phase material, or a combination thereof; and
inducing nanopores in biomembrane absorption barriers in cells or tissues or organs of said patient using said reversed cubic phase or reversed hexagonal phase material, or a combination thereof, wherein said nanopores permit said pharmaceutical active compound to pass therethrough. - View Dependent Claims (56, 57, 58, 59, 60, 61, 62, 63, 64, 78)
-
-
65. A method for transporting a compound through a biomembrane absorption barrier, comprising the steps of:
-
inducing nanopores in said biomembrane absorption barrier using a reversed cubic phase or reversed hexagonal phase material, or a combination thereof; and
passing said compound through said nanopores. - View Dependent Claims (66, 67, 68, 69, 70, 71, 72, 73, 79)
-
Specification